[go: up one dir, main page]

ATE321543T1 - Pharmazeutische zusammensetzungen mit hydroximsäurederivaten - Google Patents

Pharmazeutische zusammensetzungen mit hydroximsäurederivaten

Info

Publication number
ATE321543T1
ATE321543T1 AT96931924T AT96931924T ATE321543T1 AT E321543 T1 ATE321543 T1 AT E321543T1 AT 96931924 T AT96931924 T AT 96931924T AT 96931924 T AT96931924 T AT 96931924T AT E321543 T1 ATE321543 T1 AT E321543T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
hydroximic acid
compositions containing
acid derivatives
damages
Prior art date
Application number
AT96931924T
Other languages
English (en)
Inventor
Nagy Peter Literati
Balazs Suemegi
Laszlo Vigh
Bruno Maresca
Original Assignee
N Gene Res Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by N Gene Res Lab Inc filed Critical N Gene Res Lab Inc
Application granted granted Critical
Publication of ATE321543T1 publication Critical patent/ATE321543T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/539—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more oxygen atoms in the same ring, e.g. dioxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
AT96931924T 1995-09-29 1996-09-26 Pharmazeutische zusammensetzungen mit hydroximsäurederivaten ATE321543T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9502843A HU9502843D0 (en) 1995-09-29 1995-09-29 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
ATE321543T1 true ATE321543T1 (de) 2006-04-15

Family

ID=10987259

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96931924T ATE321543T1 (de) 1995-09-29 1996-09-26 Pharmazeutische zusammensetzungen mit hydroximsäurederivaten

Country Status (14)

Country Link
US (1) US6306878B1 (de)
EP (2) EP1020187A1 (de)
JP (2) JP3932559B2 (de)
KR (1) KR100363069B1 (de)
CN (2) CN1104894C (de)
AT (1) ATE321543T1 (de)
AU (1) AU7092296A (de)
CA (1) CA2233315C (de)
DE (1) DE69635996T2 (de)
HU (1) HU9502843D0 (de)
IL (1) IL123805A (de)
RU (1) RU2191005C2 (de)
UA (1) UA57712C2 (de)
WO (1) WO1997013504A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
HU9701081D0 (en) 1997-06-23 1997-08-28 Gene Research Lab Inc N Pharmaceutical composition of antitumoral activity
HUP9701080A3 (en) 1997-06-23 1999-05-28 Gene Res Lab Inc New York N Pharmaceutical composition containing a compound of antiviral activity and a hydroximic acid ester derivative
CA2319131A1 (en) * 1998-01-26 1999-07-29 Walter H. Moos Mitochondria protecting agents for treating mitochondria associated diseases
CA2329709A1 (en) * 1998-04-24 1999-11-04 Mitokor Compounds and methods for treating mitochondria-associated diseases
WO2000007580A2 (en) * 1998-08-03 2000-02-17 N-Gene Kutató Kft. Pharmaceutical compositions against autoimmune diseases
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
HUP0001583A2 (hu) 2000-04-18 2002-11-28 BIOREX Kutató és Fejlesztő Rt. Egy piridin-1-oxid-származék és eljárás annak átalakítására gyógyászati hatású vegyületekké
HU228783B1 (en) * 2001-07-26 2013-05-28 Greenearth Cleaning Dry cleaning apparatus and method capable of utilizing a siloxane solvent
AU2003202104B8 (en) 2002-01-11 2008-10-02 Cytrx Corporation Carboxamidine derivatives and their use in the treatment of vascular diseases
US20070027076A1 (en) 2003-09-09 2007-02-01 Fumapham Ag Use of fumaric acid derivatives for treating cardiac insufficiency, and asthma
HUP0303584A3 (en) * 2003-10-30 2009-12-28 Cytrx Corp Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
HUP0401177A2 (en) * 2004-06-14 2007-09-28 N Gene Res Lab Inc Pharmaceutical composition for increasing the mitochondrial genesis
HUP0500145A2 (en) * 2005-01-28 2006-11-28 Gene Res Lab N Use of o-(3-piperidino-2-hydroxy-1-propyl)-nicotinic amidoxime for preparation of medicaments against oral diseases
US20080108602A1 (en) * 2006-11-02 2008-05-08 N-Gene Research Laboratories, Inc. Prevention of obesity in antipsychotic, antidepressant and antiepileptic medication
US7763601B2 (en) * 2006-11-02 2010-07-27 N-Gene Research Laboratories, Inc. Prevention and treatment of obesity
EP2680008A1 (de) 2007-02-08 2014-01-01 Biogen Idec MA Inc. Nrf2-screening-Assays sowie entsprechende Verfahren und Zusammensetzungen
US20090281143A1 (en) * 2007-12-10 2009-11-12 N-Gene Research Laboratories, Inc. Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
HUP1100444A2 (en) 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
HUP1100445A2 (en) * 2011-08-17 2013-02-28 Pharma Gene Sa Pharmaceutical composition
CN102408411B (zh) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
EP3263104A1 (de) * 2016-07-01 2018-01-03 N-Gene Research Laboratories Inc. Verwendung von bgp15 zur stimulierung der mitochondrialen fusion
EP3263105A1 (de) 2016-07-01 2018-01-03 Montana State University Verwendung von bgp15 zur behandlung von familiärer dysautonomie
EP3634411B1 (de) 2017-06-08 2023-09-20 N-Gene Research Laboratories Inc. Verfahren zur behandlung von nash und zur verhinderung von nash-induziertem hcc
HUP1800298A1 (hu) 2018-08-30 2020-05-28 N Gene Res Laboratories Inc Gyógyszerkombináció béta-receptor blokkolók hatásának módosítására és a mellékhatások csökkentésére
IL303026A (en) 2020-11-19 2023-07-01 Zevra Denmark As Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4308399A (en) * 1977-08-30 1981-12-29 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. O-(3-Amino-2-hydroxy-propyl)-amidoxime derivatives, process for the preparation thereof and pharmaceutical compositions containing same
HU207988B (en) * 1988-10-20 1993-07-28 Biorex Kutato Fejlesztoe Kft Process for producing halogenides of o-/3-amino-2-hydroxy-propyl/hydroximic acid and pharmaceutical compositions containing them as active components
EP0758315B1 (de) * 1994-05-06 1998-08-26 Biorex Kutato Es Fejlesztö Rt. Hydroximsäurederivate, diese enthaltende pharmazeutische zubereitungen und verfahren zu deren herstellung

Also Published As

Publication number Publication date
CN1200670A (zh) 1998-12-02
IL123805A0 (en) 1998-10-30
JP2001519756A (ja) 2001-10-23
WO1997013504A1 (en) 1997-04-17
CN1104894C (zh) 2003-04-09
KR100363069B1 (ko) 2003-01-29
CN1263763A (zh) 2000-08-23
DE69635996D1 (de) 2006-05-18
KR19990063907A (ko) 1999-07-26
US6306878B1 (en) 2001-10-23
EP0852495B1 (de) 2006-03-29
IL123805A (en) 2001-10-31
CA2233315C (en) 2007-12-04
DE69635996T2 (de) 2007-03-15
AU7092296A (en) 1997-04-30
RU2191005C2 (ru) 2002-10-20
HU9502843D0 (en) 1995-11-28
JP2000302676A (ja) 2000-10-31
UA57712C2 (uk) 2003-07-15
CA2233315A1 (en) 1997-04-17
EP1020187A1 (de) 2000-07-19
EP0852495A1 (de) 1998-07-15
JP3932559B2 (ja) 2007-06-20

Similar Documents

Publication Publication Date Title
ATE321543T1 (de) Pharmazeutische zusammensetzungen mit hydroximsäurederivaten
RU95101048A (ru) Производные пролинамида, фармкомпозиция на их основе
ATE185792T1 (de) Stilbenderivate und diese enthaltende pharmazeutische zusammensetzungen
LU91076I9 (en) 4&#34;-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
DE69223914D1 (de) 4-substituierte-2-Deoxy-2,3-Didehydro Alpha-D-Neuraminsäure antivirale Derivate
DK0889875T3 (da) Cycloproylalkansyrederivater
ATE260255T1 (de) 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate
BR9908545A (pt) Derivado de piperidina, processo para a preparação do mesmo, composto, processo para a preparação do mesmo, e, composição farmacêutica
DK0516941T3 (da) Pyrazolopyridinforbindelser og fremgangsmåder til fremstilling deraf
PT992509E (pt) Novos derivados macrolidos
MD1560F2 (en) Cyclic compounds, pharmaceutical compositions on base thereof and methods of treatment of infections or diseases provoked by retroviruses.
TR200000153T2 (tr) İl-5 inhibite eden 6-azaurasil türevleri.
ATE122348T1 (de) Antipsychotische 3-piperazinylbenzazolderivate.
AU5879798A (en) Agents inhibiting progress of pterygium and postoperative recurrence of the same
DE69330601D1 (de) Serotoninergische ergolin derivate
DE69600272D1 (de) Chinolin-4-carbonylguanidin-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen
DE69001004D1 (de) Zusammensetzung gegen leberkrankheiten.
AU7424394A (en) 3- or 4-glycosyloxybenzopyran derivatives and antiallergic agents containing the derivatives as active ingredients
DE69908855D1 (de) 9a, 11b-dehydro Derivative von 9-oxime-3-keto-6-0-methylerythromycin
ATE21908T1 (de) Derivate von 1,4-diaminocyclitol, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
IL108068A0 (en) Cephem derivatives and pharmaceutical compositions containing the same
BR9915898A (pt) Compostos, composição farmacêutica, e, utilização de um composto
DK0823254T3 (da) Hidtil ukendt anvendelse af pyrazolopyridinforbindelser

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0852495

Country of ref document: EP

REN Ceased due to non-payment of the annual fee